Extra chemotherapy after surgery for peritoneal mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding more chemotherapy directly into the belly after surgery can improve outcomes for people with a specific type of peritoneal mesothelioma. It may help reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of epithelioid peritoneal mesothelioma.
- You are planning to have surgery to remove all visible cancer in the belly.
- You are in generally good health (able to care for yourself and be active).
- You have not had chemotherapy or immunotherapy for peritoneal mesothelioma before, and you have not had platinum-based chemotherapy.
- You are not pregnant or breastfeeding, and you agree to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a test on your tumor tissue to find which chemotherapy drugs work best for you, after standard surgery and heated chemotherapy. It aims to make your treatment more effective by choosing drugs that match your cancer.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy and a targeted therapy for people with advanced mesothelioma who have not had treatment before. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy helps people with malignant mesothelioma live longer and feel better. It's for patients who can't have surgery or radiation, and it may be an option if you haven't had treatment before or have had limited prior treatment.
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
This Phase 1/2 study tests the immune medicines durvalumab and tremelimumab, with or without chemotherapy, given before surgery for mesothelioma. It aims to shrink the tumor and improve safety and outcomes so more patients can have their cancer fully removed.
This Phase 1 trial tests a treatment that delivers heated chemotherapy directly into the abdomen (HIPEC) for certain cancers that have spread only within the abdominal lining. It aims to see how safely and effectively this approach works, especially when doctors can remove as much tumor as possible.
Hear when a new Peritoneal Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.